Bridging the Gap: Addressing Unmet Needs in Cardiology, Neuroscience, and Respiratory Trials

For many neurological, respiratory, and cardiovascular clinical studies, identifying eligible participants is far more difficult than prevalence statistics would suggest. Even though these conditions affect millions of people worldwide, enrollment challenges often resemble those seen in rare disease research. In practice, sponsors are frequently searching for a narrow subset of patients within a very large population, which creates the same recruitment pressures, delays, and feasibility risks associated with truly rare indications.

Respiratory trials illustrate this dynamic clearly. Although chronic obstructive pulmonary disease (COPD), asthma, and related conditions represent a substantial global disease burden, many studies focus on highly specific disease phenotypes, such as high-inflammatory asthma or narrowly defined COPD subtypes. Patients who meet these criteria may represent only a small fraction of the broader population, even in regions where respiratory disease is common.

A similar pattern is seen in neurological, psychiatric, and cardiovascular research. These trials often target tightly defined disease states, symptom profiles, or treatment histories to isolate drug effects and reduce variability. While this approach may support statistical clarity, it dramatically narrows the eligible patient pool. As a result, study teams are effectively searching for “needles in a haystack” — patients who meet stringent protocol requirements but may not reflect how these diseases present and are managed in real-world clinical practice.

The recruitment challenges created by narrowly defined disease targets are often compounded by highly restrictive inclusion and exclusion criteria. In many cases, these criteria are designed to reduce variability and simplify data interpretation. However, when multiple restrictions are layered together, the cumulative effect can unintentionally exclude large portions of the real-world patient population.

Respiratory trials provide a clear example. Nearly all COPD studies exclude patients who also carry an asthma diagnosis, and asthma trials typically apply the reverse restriction. Given the significant overlap between these conditions, a large fraction of COPD patients fall into an excluded category. As a result, the majority of individuals living with these diseases are never evaluated for safety or efficacy, despite being the exact patients likely to receive these therapies after approval.

Cardiovascular trials face similar constraints. Cardiovascular disease frequently coexists with diabetes, renal impairment, and other chronic conditions, yet many protocols impose strict cutoffs for body mass index (BMI) or laboratory markers of kidney function. These thresholds often eliminate patients who reflect standard clinical practice, further narrowing enrollment and limiting insight into how therapies perform in patients with common comorbidities. When trials systematically exclude patients with common comorbidities, clinicians are left with limited evidence to guide treatment decisions in the real-world populations that will ultimately receive these therapies.

Psychiatric trials, particularly those investigating depression, introduce another layer of complexity. Many studies exclude individuals classified as having treatment-resistant depression, a determination that requires specific scoring systems and retrospective assessment of prior treatment response. In routine care, however, clinicians do not rely solely on these formal definitions when making clinical decisions. When new medications with improved tolerability become available, physicians often prescribe them based on clinical judgment rather than strict categorizations. As a result, patients who would be considered appropriate candidates in practice may be excluded in trials.

Compounding this issue, many protocols exclude patients described as having tachyphylaxis — broadly defined as a loss of response after prolonged treatment. In practice, the timeframes used to define tachyphylaxis vary widely across studies and can be as short as a few months. In many cases, this reflects relapse rather than a true pharmacologic loss of response. By conflating these phenomena, protocols may exclude large numbers of patients who could reasonably benefit from investigational therapies.

When layered together, these exclusionary criteria transform already challenging trials into exercises in extreme selectivity. Enrollment becomes a search for patients who satisfy highly specific definitions rather than those who reflect the broader disease population. At the same time, the resulting data increasingly diverge from real-world clinical conditions, limiting the relevance of trial outcomes for everyday medical practice.

Beyond the challenge of identifying eligible participants, neuroscience, respiratory, and cardiovascular trials each face disease-specific obstacles that complicate data quality, interpretation, and long-term study execution.

In neurology and psychiatry, subjectivity remains a central challenge. Many endpoints rely on questionnaires, rating scales, and algorithm-based assessments that translate patient experiences into numerical scores. While these tools are designed to standardize evaluation, they remain inherently dependent on human interpretation. Cognitive and neuropsychiatric studies face an additional hurdle in the form of elevated placebo response.

To standardize subjective rating scales, some sponsors require participants to undergo centralized remote assessments to confirm eligibility. While intended to improve consistency, this approach can increase burden for both patients and sites without necessarily improving data quality. Patients may be reluctant to discuss sensitive symptoms with unfamiliar evaluators over the phone, which can lead to inaccurate assessments. In addition, several psychiatric rating scales require evaluators to assess physical appearance or behavioral cues that cannot be reliably captured in audio-only interactions and were not validated for phone administration. Repeated interviews conducted for eligibility confirmation may also unintentionally amplify placebo effects, making it harder to distinguish true drug signal from study-related interaction.

Cardiovascular trials introduce a different set of constraints. To preserve clean, interpretable endpoints, many protocols require patients to remain on stable background medications for three to five years. In reality, medication use is rarely static over such long periods. Patients may discontinue or switch therapies owing to side effects, changing clinical guidance, or loss of insurance coverage. Despite this, many studies provide limited mechanisms to ensure both continuous access to required medications and consistent oversight of adherence throughout the full duration of the trial. Without structured monitoring or support, changes in background therapy may occur unnoticed, introducing variability that can complicate interpretation of long-term outcomes.

Respiratory trials are particularly vulnerable to environmental variability. Weather patterns, seasonal allergens, and acute exacerbations may dramatically alter disease markers outside the controlled setting of the clinic. Patients with asthma, for example, may experience significant changes in symptoms or inflammatory flares away from scheduled visits. These data are clinically meaningful but difficult to capture in real time. Biomarkers also fluctuate seasonally, meaning that laboratory results obtained in winter may look very different from those collected during peak allergy seasons. Because few patients have consistent, year-round pulmonary and inflammatory data available, screening failure rates in respiratory trials may reach 85–90%.

Cardiovascular studies also face persistent challenges related to demographic variability. Symptoms often present differently in men and women. Women are less likely to be diagnosed due in part to atypical symptom presentation and a tendency to attribute warning signs to non-cardiac causes, such as gastrointestinal issues or anxiety. When data are aggregated without accounting for these differences, treatment effects may be obscured or misinterpreted. Similar risks arise when ethnic and racial differences in disease presentation and drug response are not adequately considered, further complicating both enrollment and analysis.

Neurological, cardiovascular, and respiratory diseases are often long-term, complex conditions managed through sustained relationships between patients and their physicians. For many patients, these relationships are built on trust developed over years of care. Entering a clinical trial may feel disruptive, particularly when it involves unfamiliar investigators, new protocols, or uncertainty about how care will be managed during and after the study.

In psychiatry, these concerns are particularly pronounced. Community psychiatrists who treat patients with serious mental illness are often reluctant to refer individuals into clinical trials based on past experiences where patients were removed from stable standard-of-care regimens, assigned to placebo or experimental treatments, then relapsed without clearly defined pathways for re-stabilization. When a patient worsens during a study and is simply referred back to their community provider without structured support, it damages clinical stability and professional trust. From the referring physician’s perspective, trial participation may introduce avoidable risk if safeguards are not explicitly built into the protocol.

This history shapes referral behavior, even when innovative therapies are urgently needed. Clinicians may hesitate if protocols do not clearly specify how relapses will be managed, how treatment transitions will be handled, and who bears responsibility for stabilizing patients if symptoms worsen during participation. Without those protections, research may be perceived as competing with routine care rather than complementing it.

Cardiology and respiratory practices face distinct but related barriers. Specialists in these fields are often among the busiest clinicians in medicine, with limited time to evaluate research opportunities. Concerns about administrative burden, legal complexity, and potential disruption to established patient relationships quickly discourage engagement. Some physicians worry that participation could fragment care or that patients may not return to their practice after enrollment.

To make this model workable, sponsors and CROs must move beyond general assurances and address these concerns directly within study design. Communication with referring physicians must improve, but communication alone is insufficient, particularly in psychiatry. Protocols must include clearly specified, sponsor-supported pathways for managing relapse and re-stabilization when symptoms worsen during a trial. Investigators cannot reassure community providers if protocol restrictions prevent them from delivering appropriate clinical care.

Embedding relapse management plans into the protocol not only protects patients but also strengthens trust with referring clinicians. When sites confidently state that patients will be treated and supported if their symptoms or condition worsens, participation becomes a partnership rather than a perceived risk. Clarified legal processes, streamlined administrative requirements, and reduced site-level burden promote more effective engagement Together, these measures help reframe clinical research as an extension of care that supplements community practice, reduces stigma associated with psychiatric trials, and expands access to innovative therapies without compromising patient safety or continuity.

Advances in digital technologies, such as electronic consent (eConsent), electronic patient-reported outcomes (ePROs), wearables, and telehealth, alongside the growing use of in-home trial services, are reshaping how sponsors think about trial design. Services such as home-based sample collection, basic physical exams, and remote monitoring have demonstrated clear value in reducing patient burden. As a result, even sponsors running studies in complex neurological, respiratory, and cardiovascular populations are beginning to integrate these approaches into their protocols. Together, digital tools and home trial services make participation more feasible for patients who struggle to attend frequent site visits due to disease severity, mobility limitations, or competing life demands.

While fully virtual neurology trials remain relatively uncommon, psychiatric studies may be particularly well suited to decentralized or hybrid models. Many assessments may be conducted remotely, and telehealth (including both video and audio) has already become a routine part of psychiatric care. Providing decentralized options for patients who live far from investigator sites offers a practical way to expand recruitment without compromising oversight or data quality.

In-home services are especially relevant for patients with advanced cardiovascular and respiratory disease. These individuals are often among those most in need of novel therapies, yet they face the greatest difficulty traveling to research sites. Home-based blood draws, blood pressure monitoring, and other routine assessments help bridge that gap. In respiratory research, for example, there is growing momentum behind decentralized approaches for conditions such as idiopathic pulmonary fibrosis, where disease severity and limited mobility frequently restrict trial access.

Broader adoption depends on continued evidence that decentralized and hybrid models will generate data that are comparable in quality to those collected through traditional site-based trials. As more studies demonstrate reliability and regulatory acceptability, digital tools and home trial services are likely to become standard components of trial design, used selectively and strategically to balance patient convenience with clinical rigor.

Artificial intelligence (AI) is beginning to impact multiple aspects of clinical trial planning and execution, with particularly strong potential in patient identification. Emerging tools are designed to mine neurological, respiratory, and cardiovascular health records at scale, filtering large data sets to identify patients who closely match protocol-specific eligibility criteria. For indications where suitable participants represent a small subset of a much larger population, this capability could dramatically improve feasibility and efficiency.

Realizing this potential depends on several prerequisites. Community physicians must see clear value in clinical research and feel comfortable allowing AI-enabled tools to operate within their practices. Equally important is the development of systematic approaches to data acquisition that preserve quality without increasing the burden on site staff or patients. Without thoughtful integration, even powerful tools risk becoming another layer of complexity.

When implemented well, AI serves as an objective second layer of review: verifying eligibility, flagging inconsistencies, and reducing reliance on labor-intensive manual screening. This type of system-level validation also helps address concerns around variability and bias without adding additional patient interactions that may influence study outcomes. However, AI is not positioned to replace human judgment. Trust, informed consent, and ongoing patient engagement are inherently rooted in interpersonal interactions, particularly in complex and vulnerable populations.

Used in this way, AI functions best as an amplifier of clinical expertise rather than a substitute for it, supporting better decisions while preserving the central role of investigators and site staff.

Identifying systemic challenges is only valuable if it leads to operational change. Trialmed approaches neurological, psychiatric, cardiovascular, and respiratory research with the understanding that many feasibility barriers are not theoretical; they are the product of real-world clinical friction. As a site organization embedded in patient care, Trialmed evaluates protocols through the lens of day-to-day practice: How will this function in a busy pulmonology office? How will a community psychiatrist respond? What happens if a patient relapses? What happens if a biomarker fluctuates outside the clinic visit window?

Rather than accepting protocol constraints as fixed, Trialmed works to surface these practical concerns early. In psychiatry, that means advocating for clearly defined relapse management pathways, so investigators are not prevented from stabilizing patients whose symptoms worsen during participation. In respiratory and cardiovascular research, it means addressing screen-failure drivers, environmental variability, and medication adherence realities before enrollment begins. When eligibility criteria, endpoint timing, or background therapy requirements create predictable operational strain, those issues are elevated and discussed, not simply managed downstream.

Trialmed also prioritizes intelligent patient identification and workflow efficiency. Emerging data-mining and AI tools offer the potential to triage large populations and identify appropriate candidates more efficiently, reducing manual screening burden while preserving investigator oversight. Used thoughtfully, these tools function as a second layer of validation rather than a replacement for clinical judgment, helping sites focus their time on patient engagement rather than administrative filtration.

Decentralized and hybrid trial approaches are incorporated strategically, particularly for populations with mobility limitations or severe disease. Home-based assessments, remote monitoring, and flexible visit models expand access without compromising data integrity, provided they are implemented with clear operational safeguards. For respiratory and advanced cardiovascular patients who struggle to travel, these options make participation realistic rather than aspirational.

Equally important is reducing stigma and strengthening referral trust. Trialmed positions research as a supplement to routine care rather than a competitor to it. By sharing data with referring physicians, maintaining open communication, and ensuring that patients who experience clinical worsening are actively stabilized rather than simply referred back, our organization works to rebuild confidence among community providers. Participation should enhance patient care, not fragment it.

The underlying philosophy is straightforward: trials must function within the realities of clinical medicine. Disease complexity cannot be removed, but protocol design, site processes, and patient support structures can be aligned more closely with how care is delivered. When that alignment occurs, enrollment improves, data quality strengthens and trust among patients, physicians, and investigators becomes an asset rather than a barrier.

Neurological, psychiatric, respiratory, and cardiovascular diseases affect hundreds of millions of people worldwide, often diminishing both quality of life and long-term health outcomes. Continued progress in these areas depends on sustained investment in understanding disease biology and translating that knowledge into new therapeutic options. However, even the most promising scientific advances cannot reach patients without rigorous evaluation to establish safety and effectiveness.

Clinical trials remain the foundation of that evaluation process. Every approved medicine has passed through clinical development, relying on individuals who choose to participate in research. Some volunteers enroll because they are living with serious illness and hope for improvement. Others are healthy individuals who participate to help determine whether new treatments can be used safely. In both cases, participation reflects an act of trust in the research process and a willingness to contribute to medical progress.

These individuals are not passive subjects of experimentation. They are active partners in discovery, enabling therapies to move from laboratory concepts to real-world care. Without their involvement, advances in treatment for complex neurological, respiratory, and cardiovascular conditions would stall. Recognizing the essential role participants play reinforces why trial design, execution, and patient experience must remain central considerations in clinical research — and why continued efforts to reduce barriers to participation matter.